These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 16556488)
1. Activity of blue green microalgae extracts against in vitro generated Staphylococcus aureus with reduced susceptibility to vancomycin. Bhateja P; Mathur T; Pandya M; Fatma T; Rattan A Fitoterapia; 2006 Apr; 77(3):233-5. PubMed ID: 16556488 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus. Fritsche TR; Rhomberg PR; Sader HS; Jones RN Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361 [TBL] [Abstract][Full Text] [Related]
3. Rapid detection of Staphylococcus aureus strains having reduced susceptibility to vancomycin using a chemiluminescence-based drug-susceptibility test. Tajima Y; Komatsu M; Ito T; Hiramatsu K J Microbiol Methods; 2007 Sep; 70(3):434-41. PubMed ID: 17655957 [TBL] [Abstract][Full Text] [Related]
4. The need for accuracy in performing vancomycin intermediate resistant Staphylococcus aureus (VISA) and hetero--VISA detection methods. Wootton M Int J Antimicrob Agents; 2006 Dec; 28(6):586. PubMed ID: 17049817 [No Abstract] [Full Text] [Related]
5. Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA). Appelbaum PC Int J Antimicrob Agents; 2007 Nov; 30(5):398-408. PubMed ID: 17888634 [TBL] [Abstract][Full Text] [Related]
6. Effect of Saliva miltiorrhiza bunge on antimicrobial activity and resistant gene regulation against methicillin-resistant Staphylococcus aureus (MRSA). Lee JW; Ji YJ; Lee SO; Lee IS J Microbiol; 2007 Aug; 45(4):350-7. PubMed ID: 17846590 [TBL] [Abstract][Full Text] [Related]
7. Susceptibilities of healthcare- and community-associated methicillin-resistant staphylococci to the novel des-F(6)-quinolone DX-619. Watanabe S; Ito T; Hiramatsu K J Antimicrob Chemother; 2007 Dec; 60(6):1384-7. PubMed ID: 17890283 [TBL] [Abstract][Full Text] [Related]
8. The activity of daptomycin against wild-type Staphylococcus aureus and strains with reduced susceptibility to vancomycin. Sader HS; Jones RN Clin Infect Dis; 2006 Sep; 43(6):798-9; author reply 799-800. PubMed ID: 16912964 [No Abstract] [Full Text] [Related]
9. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus. Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538 [TBL] [Abstract][Full Text] [Related]
10. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Huang YT; Liao CH; Teng LJ; Hsueh PR Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Barcia-Macay M; Lemaire S; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F J Antimicrob Chemother; 2006 Dec; 58(6):1177-84. PubMed ID: 17062609 [TBL] [Abstract][Full Text] [Related]
12. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Strukova EN; Smirnova MV; Vostrov SN; Lubenko IY; Firsov AA; Zinner SH; Portnoy YA Int J Antimicrob Agents; 2009 Mar; 33(3):251-4. PubMed ID: 19095420 [TBL] [Abstract][Full Text] [Related]
13. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Garrison MW; Nuemiller JJ Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Tsuji BT; Rybak MJ; Lau KL; Sakoulas G Antimicrob Agents Chemother; 2007 Mar; 51(3):1089-91. PubMed ID: 17158941 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Kuti JL; Kiffer CR; Mendes CM; Nicolau DP Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus. Park YS; Shin WS; Kim SK J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852 [TBL] [Abstract][Full Text] [Related]
18. Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains. Drummelsmith J; Winstall E; Bergeron MG; Poirier GG; Ouellette M J Proteome Res; 2007 Dec; 6(12):4690-702. PubMed ID: 17997515 [TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004). Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446 [TBL] [Abstract][Full Text] [Related]
20. Key considerations in the treatment of complicated staphylococcal infections. Jones RN Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]